We're pleased to announce the expansion of our BGE-102 clinical development program into ophthalmology. NLRP3 inflammasome activation is a central driver of serious retinal diseases where inflammation is a key feature—including diabetic macular edema (DME) and geographic atrophy. We plan to initiate a Phase 1b/2a proof-of-concept (POC) trial in DME in mid-2026, to run in parallel with the BGE-102 Phase 2a cardiovascular risk trial initiating 1H26. Read the release: ir.bioagelabs.com/news-relea… Key points: • BGE-102's exceptional tissue penetration enables potential therapeutic retinal exposure with convenient oral delivery—offering a potential alternative to frequent intravitreal injections • In preclinical models of DME, oral BGE-102 demonstrated dose-dependent preservation of retinal vascular integrity, achieving up to 100% reduction in vascular permeability • The randomized, controlled POC trial will evaluate BGE-102 as monotherapy and in combination with a VEGF inhibitor, with results anticipated mid-2027 • In ongoing Phase 1 trial, BGE-102 has demonstrated robust reductions in key inflammatory biomarkers of cardiovascular risk, including hsCRP, IL-6, and IL-1β Clinical milestones for BGE-102: • Full data readout of Phase 1 anticipated 1H26 • CV risk Phase 2a POC trial initiates 1H26, with data anticipated 2H26 • DME Phase 1b/2a POC trial initiates mid-2026, with data anticipated mid-2027 Aging biology in action: NLRP3-driven inflammation is a hallmark of aging implicated in diseases across multiple organ systems—including the retina, where inflammasome activation contributes to conditions like DME and geographic atrophy. With its high potency, exceptional tissue penetration, and early clinical evidence of  best-in-class reductions in inflammatory markers of cardiovascular risk, BGE-102 has the potential to be a "pipeline in a pill": a single oral therapy addressing NLRP3-driven inflammation across cardiovascular, CNS, and ocular diseases. We look forward to sharing updates as we advance BGE-102 across multiple indications!

We’re pleased to announce our new publication today in Journal of Experimental Medicine describing the discovery and characterization of the novel class of NLRP3 inhibitors that includes BGE-102, a brain-penetrant, orally available small molecule that BioAge is initially developing for obesity. rupress.org/jem/article/222/… Key findings of the study: • Novel mechanism: Our compounds bind to a previously unknown site on NLRP3, distinct from all other known inhibitors, offering a new approach to modulating inflammasome activity • Exceptional potency: Nanomolar inhibition of human NLRP3 across multiple cell types and inflammatory triggers • In vivo efficacy: Robust NLRP3 inhibition in humanized mouse models, supporting translational potential NLRP3 is a key driver of age-related inflammation that has been implicated in a broad range of diseases, including neurodegenerative conditions and cardiovascular disease as well as metabolic disorders such as obesity.  In preclinical obesity models, BGE-102 monotherapy achieved dose-dependent weight loss comparable to GLP-1 agonists, and additive effects in combination with semaglutide. A Phase 1 trial of BGE-102 was initiated in August, with single ascending dose (SAD) data anticipated by the end of the year. Learn more about the Phase 1 trial and preclinical obesity data: ir.bioagelabs.com/news-relea… Congratulations to our collaborators @Rebecca_Coll at Queen’s University Belfast, @Geyer_lab of the University of Bonn, and @benedicte_py of CIRI/Inserm, along with BioAge’s exceptional scientific team, on the publication of this important study!